vs
PERDOCEO EDUCATION Corp（PRDO）与REPLIGEN CORP（RGEN）财务数据对比。点击上方公司名可切换其他公司
PERDOCEO EDUCATION Corp的季度营收约是REPLIGEN CORP的1.1倍（$211.6M vs $197.9M），PERDOCEO EDUCATION Corp同比增速更快（20.0% vs 13.6%），PERDOCEO EDUCATION Corp自由现金流更多（$37.9M vs $17.6M），过去两年REPLIGEN CORP的营收复合增速更高（14.4% vs 12.2%）
Perdoceo Education是美国上市营利性教育集团，前身为职业教育公司（Career Education Corporation），旗下运营五所美国营利性大学，包括美国洲际大学、科罗拉多理工大学、南加利福尼亚大学、三叉戟国际大学及圣奥古斯丁健康科学大学，业务覆盖高等教育、职业教育及健康科学相关教育领域。
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
PRDO vs RGEN — 直观对比
营收规模更大
PRDO
是对方的1.1倍
$197.9M
营收增速更快
PRDO
高出6.3%
13.6%
自由现金流更多
PRDO
多$20.3M
$17.6M
两年增速更快
RGEN
近两年复合增速
12.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $211.6M | $197.9M |
| 净利润 | — | $13.3M |
| 毛利率 | — | 52.5% |
| 营业利润率 | 19.8% | 9.0% |
| 净利率 | — | 6.7% |
| 营收同比 | 20.0% | 13.6% |
| 净利润同比 | — | 143.9% |
| 每股收益（稀释后） | $0.55 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PRDORGEN
| Q4 25 | $211.6M | $197.9M | ||
| Q3 25 | $211.9M | $188.8M | ||
| Q2 25 | $209.6M | $182.4M | ||
| Q1 25 | $213.0M | $169.2M | ||
| Q4 24 | $176.4M | $174.1M | ||
| Q3 24 | $169.8M | $154.9M | ||
| Q2 24 | $166.7M | $154.1M | ||
| Q1 24 | $168.3M | $151.3M |
净利润PRDORGEN
| Q4 25 | — | $13.3M | ||
| Q3 25 | $39.9M | $14.9M | ||
| Q2 25 | $41.0M | $14.9M | ||
| Q1 25 | $43.7M | $5.8M | ||
| Q4 24 | — | $-30.3M | ||
| Q3 24 | $38.3M | $-654.0K | ||
| Q2 24 | $38.4M | $3.3M | ||
| Q1 24 | $39.4M | $2.1M |
毛利率PRDORGEN
| Q4 25 | — | 52.5% | ||
| Q3 25 | — | 53.2% | ||
| Q2 25 | — | 50.0% | ||
| Q1 25 | — | 53.6% | ||
| Q4 24 | — | 26.1% | ||
| Q3 24 | — | 50.0% | ||
| Q2 24 | — | 49.8% | ||
| Q1 24 | — | 49.5% |
营业利润率PRDORGEN
| Q4 25 | 19.8% | 9.0% | ||
| Q3 25 | 24.1% | 8.9% | ||
| Q2 25 | 24.5% | 7.6% | ||
| Q1 25 | 24.3% | 3.9% | ||
| Q4 24 | 21.1% | -17.7% | ||
| Q3 24 | 26.4% | -5.1% | ||
| Q2 24 | 27.6% | 1.0% | ||
| Q1 24 | 27.5% | 1.3% |
净利率PRDORGEN
| Q4 25 | — | 6.7% | ||
| Q3 25 | 18.8% | 7.9% | ||
| Q2 25 | 19.6% | 8.2% | ||
| Q1 25 | 20.5% | 3.4% | ||
| Q4 24 | — | -17.4% | ||
| Q3 24 | 22.5% | -0.4% | ||
| Q2 24 | 23.0% | 2.2% | ||
| Q1 24 | 23.4% | 1.4% |
每股收益（稀释后）PRDORGEN
| Q4 25 | $0.55 | $0.24 | ||
| Q3 25 | $0.60 | $0.26 | ||
| Q2 25 | $0.62 | $0.26 | ||
| Q1 25 | $0.65 | $0.10 | ||
| Q4 24 | $0.46 | $-0.55 | ||
| Q3 24 | $0.57 | $-0.01 | ||
| Q2 24 | $0.57 | $0.06 | ||
| Q1 24 | $0.59 | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $111.0M | $767.6M |
| 总债务越低越好 | — | $542.2M |
| 股东权益账面价值 | $972.4M | $2.1B |
| 总资产 | $1.2B | $2.9B |
| 负债/权益比越低杠杆越低 | — | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资PRDORGEN
| Q4 25 | $111.0M | $767.6M | ||
| Q3 25 | $159.5M | $748.7M | ||
| Q2 25 | $172.1M | $708.9M | ||
| Q1 25 | $132.1M | $697.2M | ||
| Q4 24 | $109.1M | $757.4M | ||
| Q3 24 | $238.0M | $784.0M | ||
| Q2 24 | $127.9M | $809.1M | ||
| Q1 24 | $125.8M | $780.6M |
总债务PRDORGEN
| Q4 25 | — | $542.2M | ||
| Q3 25 | — | $537.9M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $525.6M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益PRDORGEN
| Q4 25 | $972.4M | $2.1B | ||
| Q3 25 | $997.9M | $2.1B | ||
| Q2 25 | $984.6M | $2.1B | ||
| Q1 25 | $970.3M | $2.0B | ||
| Q4 24 | $959.5M | $2.0B | ||
| Q3 24 | $935.4M | $2.0B | ||
| Q2 24 | $899.5M | $2.0B | ||
| Q1 24 | $866.1M | $2.0B |
总资产PRDORGEN
| Q4 25 | $1.2B | $2.9B | ||
| Q3 25 | $1.3B | $2.9B | ||
| Q2 25 | $1.3B | $2.9B | ||
| Q1 25 | $1.3B | $2.9B | ||
| Q4 24 | $1.2B | $2.8B | ||
| Q3 24 | $1.1B | $2.8B | ||
| Q2 24 | $1.1B | $2.9B | ||
| Q1 24 | $1.1B | $2.8B |
负债/权益比PRDORGEN
| Q4 25 | — | 0.26× | ||
| Q3 25 | — | 0.26× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.27× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $40.1M | $25.7M |
| 自由现金流经营现金流 - 资本支出 | $37.9M | $17.6M |
| 自由现金流率自由现金流/营收 | 17.9% | 8.9% |
| 资本支出强度资本支出/营收 | 1.1% | 4.1% |
| 现金转化率经营现金流/净利润 | — | 1.93× |
| 过去12个月自由现金流最近4个季度 | $216.7M | $93.9M |
8季度趋势，按日历期对齐
经营现金流PRDORGEN
| Q4 25 | $40.1M | $25.7M | ||
| Q3 25 | $41.2M | $48.1M | ||
| Q2 25 | $78.8M | $28.6M | ||
| Q1 25 | $65.1M | $15.0M | ||
| Q4 24 | $17.6M | $39.2M | ||
| Q3 24 | $51.0M | $49.3M | ||
| Q2 24 | $38.5M | $42.2M | ||
| Q1 24 | $54.5M | $44.7M |
自由现金流PRDORGEN
| Q4 25 | $37.9M | $17.6M | ||
| Q3 25 | $39.4M | $43.4M | ||
| Q2 25 | $76.0M | $21.5M | ||
| Q1 25 | $63.4M | $11.4M | ||
| Q4 24 | $16.0M | $33.6M | ||
| Q3 24 | $50.0M | $42.3M | ||
| Q2 24 | $37.7M | $37.4M | ||
| Q1 24 | $53.3M | $36.4M |
自由现金流率PRDORGEN
| Q4 25 | 17.9% | 8.9% | ||
| Q3 25 | 18.6% | 23.0% | ||
| Q2 25 | 36.3% | 11.8% | ||
| Q1 25 | 29.8% | 6.8% | ||
| Q4 24 | 9.1% | 19.3% | ||
| Q3 24 | 29.4% | 27.3% | ||
| Q2 24 | 22.6% | 24.3% | ||
| Q1 24 | 31.7% | 24.0% |
资本支出强度PRDORGEN
| Q4 25 | 1.1% | 4.1% | ||
| Q3 25 | 0.9% | 2.5% | ||
| Q2 25 | 1.3% | 3.9% | ||
| Q1 25 | 0.8% | 2.1% | ||
| Q4 24 | 0.9% | 3.2% | ||
| Q3 24 | 0.6% | 4.5% | ||
| Q2 24 | 0.5% | 3.1% | ||
| Q1 24 | 0.7% | 5.5% |
现金转化率PRDORGEN
| Q4 25 | — | 1.93× | ||
| Q3 25 | 1.03× | 3.23× | ||
| Q2 25 | 1.92× | 1.92× | ||
| Q1 25 | 1.49× | 2.57× | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.33× | — | ||
| Q2 24 | 1.00× | 12.70× | ||
| Q1 24 | 1.38× | 21.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PRDO
| CTU | $107.0M | 51% |
| AIUS | $60.8M | 29% |
| University Of St Augustine For Health Sciences Llc | $43.7M | 21% |
| Other | $1.1M | 1% |
RGEN
暂无分部数据
